Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial

  title={Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial},
  author={Byung-Koo Yoon and Juhee Chin and Jong-Won Kim and Myung Hee Shin and Soohyun Ahn and Dong-Yun Lee and Sang Won Seo and Duk L. Na},
Objective: The aim of the study was to explore the therapeutic potential of menopausal hormone therapy (MHT) in women with mild cognitive impairment (MCI). Methods: Thirty-seven postmenopausal women (age range: 57-82 y) with multiple-domain, amnestic subtype MCI were randomly assigned to either placebo (n = 18) or MHT (n = 19) for 24 months (percutaneous estradiol [E2] gel [0.1%, 2 mg/d] and oral micronized progesterone [MP4] [100 mg/d]). All participants received donepezil, and apolipoprotein… 
Hormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature.
To progress forward and allow unbiased interpretation, it is no longer acceptable to group HT formulations together as a homogenous group, and differentiation between compounds that exhibit beneficial actions and those that do not and whether these effects are specific or generalized.
Perspective: Estrogen and the Risk of Cognitive Decline: A Missing Choline(rgic) Link?
Novel hypotheses related to hormone replacement therapy and nutrient metabolism aimed at directing future preclinical and clinical investigation are highlighted, including one related to the essential nutrient choline.
A review of the impact of hormone therapy on prefrontal structure and function at menopause
  • Y. Li, J. Dreher
  • Biology
    Climacteric : the journal of the International Menopause Society
  • 2021
Human research related to the impact of MHT on structural and functional organization of the prefrontal cortex in postmenopausal women is reviewed to identify areas for future research.
The interactive impact of omega-3 fatty acids, APOE genotype and sex hormones on cognition
Cognitive and neurological impacts of menopause are indicated, which are exacerbated by APOE4, and ameliorated through high fish-oil supplementation.
The Influence of Physical Activity and Epigenomics On Cognitive Function and Brain Health in Breast Cancer
Although investigating DNA methylation has the potential to uncover the biologic foundations for understanding neurocognitive changes within the context of breast cancer and its treatment as well as the ability to understand how exercise mitigates these changes, there is a dearth of research on this topic.
White matter changes from mild cognitive impairment to Alzheimer’s disease: a meta-analysis
Objective and quantitative evidence is provided that AD is associated with FA alteration within left frontal lobe, CC, FX, HP, CG, CB, and UF may suggest the key regions of the process from MCI to AD.
Revealing the Influences of Sex Hormones and Sex Differences in Atrial Fibrillation and Vascular Cognitive Impairment
Deciphering how sex hormones and their receptor signaling (estrogen and androgen receptors) potentially impact on sex differences could help to reveal disease links between AF and VCI and identify therapeutic targets that may lead to potentially novel therapeutic interventions early in the disease course of AF andVCI.
Risks and benefits of menopausal hormone therapy
  • B. Yoon
  • Medicine
    Journal of the Korean Medical Association
  • 2019
Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with
Utilization of Human Induced Pluripotent Stem Cells-Derived In vitro Models for the Future Study of Sex Differences in Alzheimer’s Disease
Induced pluripotent stem cells (iPSCs) derived from patients can differentiate into neurons and recapitulate some aspects of AD pathogenesis, and provide opportunities to investigate sex-dependent pathogenesis and predict a suitable population for clinical trials of hormone treatment.
Royal Jelly Ameliorates Behavioral Deficits, Cholinergic System Deficiency, and Autonomic Nervous Dysfunction in Ovariectomized Cholesterol-Fed Rabbits
The findings suggested that RJ has beneficial effects in neurological disorders of postmenopausal women, which were associated with reducing cholesterol and Aβ deposition, enhancing the estrogen levels and the activities of cholinergic and antioxidant systems, and ameliorating the blood–brain barrier (BBB) permeability and restoring autonomic nervous system.


Hormone therapy in menopausal women with cognitive complaints
Potential modest negative effects on verbal memory that are consistent with previous hormone therapy trials in older women are suggested.
Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study
The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized, and women treated with o-CEE showed improvements in depression and anxiety symptoms over the 48 mo period, compared to women on placebo.
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial
The study does not support the role of estrogen for the treatment of this disease, nor does it improve global, cognitive, or functional outcomes in women with mild to moderate AD.
No additional benefit of HRT on response to rivastigmine in menopausal women with AD
Rivastigmine is an approved cholinesterase inhibitor with proven efficacy on cognitive and functional deficits in mild to moderately severe AD.1 The possibility that estrogen might enhance effects of
Cognitive effects of estradiol after menopause
Estradiol initiated within 6 years of menopause does not affect verbal memory, executive functions, or global cognition differently than therapy begun 10+ years afterMenopause, and neither benefits nor harms these cognitive abilities regardless of time since Menopause.
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
Transdermal 17β-estradiol therapy in recently postmenopausal women was associated with a reduced amyloid-β deposition, particularly in APOE ɛ4 carriers, and this finding may have important implications for the prevention of AD in post menopause, and needs to be confirmed in a larger sample.
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Estrogen therapy alone did not reduce dementia or MCI incidence and increased the risk for both end points combined and use of hormone therapy to prevent dementia or cognitive decline in women 65 years of age or older is not recommended.
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Vitamin E had no benefit in patients with mild cognitive impairment and donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, a finding supported by the secondary outcome measures.
High-dose estradiol improves cognition for women with AD
Although these findings provide further clinical evidence to support a cognitive benefit of estrogen for women with AD, studies evaluating the effect of estradiol administration, in particular, using larger sample sizes and for longer treatment durations are warranted before the therapeutic potential of estrogen replacement for Women with AD can be firmly established.